THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN

Source: USASpending · CONT_AWD_75A50124C00054_7505_-NONE-_-NONE- · As of 2026-09-30 · Last synced 2026-11-10

Dates reflect the source record. Options and extensions exist; an end date does not establish that a contract will be recompeted, renewed, or terminated.

source record id

CONT_AWD_75A50124C00054_7505_-NONE-_-NONE-

generated unique award id

CONT_AWD_75A50124C00054_7505_-NONE-_-NONE-

source

USASpending

award id piid

75A50124C00054

vendor name as awarded

AURAVAX THERAPEUTICS, INC.

vendor uei

PAN3ZK2YLAL2

agency name

Department of Health and Human Services

sub agency

Office of Assistant Secretary for Preparedness and Response

contract title or description

THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN

naics code

541714

naics description

RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)

psc code

AN14

texas nigp code

Not published

value obligated

749999

Total / ceiling as published (not obligated)

Not published

pop start date

2024-09-23T05:00:00.000Z

expiry date

2027-07-31T05:00:00.000Z

place of performance state

TX

recipient location state

TX

set aside type

NO SET ASIDE USED.

source as of

2026-09-30T05:00:00.000Z

last synced

2026-11-10T06:00:00.000Z

published

true

Source expiry field

Period of performance current end date (USASpending)